Shruti Malu, Ph.D. - Publications

Affiliations: 
2010 Immunology Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Area:
Molecular Biology

20/27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Jerby L, Shah P, Cuoco MS, Rodman C, Su M, Melms JM, Leeson R, Kanodia A, Mei S, Lin J, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Malu S, et al. Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A082  0.352
2018 Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism. PMID 29628419 DOI: 10.1016/J.Cmet.2018.02.024  0.384
2017 McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, et al. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 29267866 DOI: 10.1093/Jnci/Djx257  0.334
2017 Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications. 8: 451. PMID 28878208 DOI: 10.1038/S41467-017-00449-Z  0.352
2017 de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG. High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Translational Oncology. 10: 546-554. PMID 28654818 DOI: 10.1016/J.Tranon.2017.05.007  0.323
2016 McKenzie JA, Mbofung RM, Malu S, Hwu P. Abstract B152: Increasing the antitumor efficacy of immunotherapy in melanoma by using topoisomerase I inhibitors Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B152  0.414
2016 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, et al. Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Research. 76: 4363-4363. DOI: 10.1158/1538-7445.Am2016-4363  0.366
2016 Williams L, Malu S, McKenzie J, Mbofung R, Forget M, Bernatchez C, Hwu P. Abstract 4010: Identification of novel targeted and immunotherapy combinations by a high throughput assay of T cell-mediated cytotoxicity Immunology. 76: 4010-4010. DOI: 10.1158/1538-7445.Am2016-4010  0.315
2016 McKenzie JA, Mbofung RM, Malu S, Amaria RN, Davis RE, Zhang L, Tieu TN, Heffernan TP, Hwu P. Abstract 4002: Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398 Cancer Research. 76: 4002-4002. DOI: 10.1158/1538-7445.Am2016-4002  0.391
2016 Wang Z, Malu S, Peng W, McKenzie J, Mbofung R, Williams L, Seth S, Heffernan T, Hwu P. Abstract 1441: Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens Cancer Research. 76: 1441-1441. DOI: 10.1158/1538-7445.Am2016-1441  0.366
2015 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.Cd-15-0283  0.368
2015 Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma. 2015: 547460. PMID 25705114 DOI: 10.1155/2015/547460  0.325
2014 Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, Haymaker C, Bernatchez C, Huls H, Wang E, Marincola FM, Hwu P, Cooper LJ, Radvanyi LG. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 37: 448-60. PMID 25304728 DOI: 10.1097/Cji.0000000000000056  0.318
2014 Francis DB, Kozlov M, Chavez J, Chu J, Malu S, Hanna M, Cortes P. DNA Ligase IV regulates XRCC4 nuclear localization. Dna Repair. 21: 36-42. PMID 24984242 DOI: 10.1016/J.Dnarep.2014.05.010  0.634
2013 Forget M, Malu S, Liu H, Toth C, Maiti S, Kale C, Bernatchez C, Huls H, Wang E, Hwu P, Cooper LJ, Radvanyi LG. Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy Journal For Immunotherapy of Cancer. 1: 8. DOI: 10.1186/2051-1426-1-S1-P8  0.331
2013 Mbofung R, Peng W, Liu C, Xu C, Malu S, Yang Y, Ma W, Wang Z, Overwijk W, Davis E, Lee B, Hwu P. The role of transcription factor Runx2 in tumor infiltrating T cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P23  0.368
2013 Malu S, Mbofung R, Khalili J, Satani N, Forget M, Haymaker C, Muller F, Bernatchez C, Radvanyi L, Hwu P. Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity Journal For Immunotherapy of Cancer. 1: 164. DOI: 10.1186/2051-1426-1-S1-P164  0.39
2012 De Ioannes P, Malu S, Cortes P, Aggarwal AK. Structural basis of DNA ligase IV-Artemis interaction in nonhomologous end-joining. Cell Reports. 2: 1505-12. PMID 23219551 DOI: 10.1016/J.Celrep.2012.11.004  0.628
2012 Malu S, Malshetty V, Francis D, Cortes P. Role of non-homologous end joining in V(D)J recombination. Immunologic Research. 54: 233-46. PMID 22569912 DOI: 10.1007/S12026-012-8329-Z  0.627
2012 Malu S, De Ioannes P, Kozlov M, Greene M, Francis D, Hanna M, Pena J, Escalante CR, Kurosawa A, Erdjument-Bromage H, Tempst P, Adachi N, Vezzoni P, Villa A, Aggarwal AK, et al. Artemis C-terminal region facilitates V(D)J recombination through its interactions with DNA Ligase IV and DNA-PKcs. The Journal of Experimental Medicine. 209: 955-63. PMID 22529269 DOI: 10.1084/Jem.20111437  0.652
Low-probability matches (unlikely to be authored by this person)
2020 Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, et al. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy : Cii. PMID 33123754 DOI: 10.1007/s00262-020-02748-9  0.269
2018 Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29496759 DOI: 10.1158/1078-0432.Ccr-17-2483  0.268
2021 Frangieh CJ, Melms JC, Thakore PI, Geiger-Schuller KR, Ho P, Luoma AM, Cleary B, Jerby-Arnon L, Malu S, Cuoco MS, Zhao M, Ager CR, Rogava M, Hovey L, Rotem A, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nature Genetics. PMID 33649592 DOI: 10.1038/s41588-021-00779-1  0.249
2018 Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Malu S, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 175: 984-997.e24. PMID 30388455 DOI: 10.1016/J.Cell.2018.09.006  0.233
2006 Mukherjee S, Ahmed A, Malu S, Nandi D. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2. Journal of Leukocyte Biology. 80: 66-74. PMID 16624934 DOI: 10.1189/jlb.0505260  0.145
2003 Malu S, Srinivasan S, Kumar Maiti P, Rajagopal D, John B, Nandi D. IFN-gamma bioassay: development of a sensitive method by measuring nitric oxide production by peritoneal exudate cells from C57BL/6 mice. Journal of Immunological Methods. 272: 55-65. PMID 12505712 DOI: 10.1016/S0022-1759(02)00424-6  0.117
2020 Tan B, Malu S, Roth KD. Development of ion pairing LC-MS/MS method for itaconate and cis-aconitate in cell extract and cell media. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1146: 122120. PMID 32361631 DOI: 10.1016/j.jchromb.2020.122120  0.096
Hide low-probability matches.